Oncology

The Pharmacy Times® Pharmacy Focus podcast provides the latest industry news and information, thought-leader insights, clinical updates, patient counseling tools, and innovative solutions for the everyday practice and business of pharmacy.

Researchers analyzed the survey responses of more than 1400 current users of e-cigarette and related products from 18 to 64 years of age, evenly divided among male and female, who took part in a national online survey in 2016.

Devimistat is designed to be used in conjunction with other drugs to make cancer cells more sensitive to treatment.

In a trial, 91% of patients rated Sutab as very easy to tolerable to consume, and 78% said they would request Sutab again for a future colonoscopy.

Pharmacists and other medical experts also have a great opportunity to use social media to correct misconceptions, provide guidance, and steer patients toward credible sources.

The FDA approved FoundationOne Liquid CDx as a companion diagnostic with olaparib for certain patients with metastatic castration-resistant prostate cancer.

Pharmacy Times® interviewed Petros Grivas, MD, PhD, associate professor at the University of Washington and Fred Hutchinson Cancer Research Center and a medical oncologist at Seattle Cancer Care Alliance, on the work of the COVID-19 and Cancer Consortium.

Patients recently diagnosed with cancer are significantly more likely to quit smoking and remain tobacco-free if they receive frequent phone counseling over an extended period of time.

A new breast cancer combination treatment may help patients with certain gene mutations, according to a study published in Molecular Cell.

Black women experience longer waiting periods before treatment is initiated than White women following a breast cancer diagnosis, as well as a prolonged treatment duration compared with White women.

Angiotensin receptor II blockers are often prescribed to control hypertension or for heart failure, kidney failure, or following a heart attack.

The United States Preventive Services Task Force updates recommends that colorectal cancer screening begin 5 years earlier, at age 45 instead of age 50.

Study to evaluate paclitaxel plus encequidar with dostarlimab +/- carboplatin in patients with breast cancer.

Data show that children with cancer who are experiencing neighborhood poverty and rely on public health insurance have an increased risk of death with stem cell treatment.

FDA lift clinical hold placed on the phase 1 PSMA-101-001 study of the chimeric antigen receptor T-cell therapy P-PSMA-101 in patients with metastatic castration-resistant prostate cancer.

FDA approves the cobas EGFR Mutation Test v2 as a companion diagnostic for EGFR TKIs in the treatment of EGFR-mutated non–small cell lung cancer.

The FDA granted priority review to a supplemental biologics license application for cemiplimab-rwlc for the frontline treatment of patients with locally advanced or metastatic non–small cell lung cancer.

Approximately 30% of women gain weight following chemotherapy for breast cancer, gut bacteria may be why.

The FDA granted priority review to a supplemental biologics license application for trastuzumab deruxtecan in patients with HER2-positive gastric or gastroesophageal junction adenocarcinoma.

FDA approves FoundationOne Liquid CDx as a companion diagnostic for alpelisib in advanced or metastatic breast cancer, rucaparib in advanced ovarian cancer, and alectinib in a specific type of metastatic non–small cell lung cancer.

An axillary lymph node dissection, which is the surgical removal of 10 to 20 lymph nodes from the breast, is a procedure conducted in up to 25% of women with breast cancer to disable symptoms of arm swelling.

Lipid-lowering medication may be an effective adjuvant cancer therapy.

The FDA has approved the FoundationOne CDx (F1CDx) comprehensive genomic test as a companion diagnostic for larotrectinib (Vitrakvi) to identify patients with NTRK1/2/3 gene fusions across all solid tumors.

Cholesterol-lowering statins have been found to potentially reduce the risk of cancer via a pathway that is unrelated to its impact on cholesterol, according to a recent study.

The specialty pipeline continues to grow at a rapid pace with a number of FDA approvals in 2019 for either new therapies or first in class for certain conditions, and many more drugs in development.

Patients with current or former smoking status may be at an increased risk of severe illness due to COVID-19.

The FDA granted osimertinib (Tagrisso) priority review designation for the adjuvant treatment of patients with early-stage EGFR-mutated non–small cell lung cancer following complete tumor resection with curative intent.

oNKord is a natural killer cellular immunotherapy product, meaning it can play an important role in controlling and curing both solid and hematological malignancies.